The Indian CRO market has grown at a CAGR of 5.51% during the period between 2017 and 2020 and was valued at USD 956.8 million in 2020. The market is further expected to reach USD 1,883.0 million by 2027 with a CAGR of 10.75%. Among the factors contributing to the growth of the Indian CRO space are the rapidly growing field of oncology studies, the booming pharmaceutical industry, and various initiatives from the Indian government.However, over the past two decades, with more systematic functioning of DCGI and various governmental initiatives regarding clinical studies new opportunities related to the industry has been blooming giving birth to new verticals like SMOs. But a gap between the Indian pharmaceutical startups and large CROs has been still noticed in terms of contraction of budget and affordability. This is where Croissance Clinical Research came into existence in 1993 as a biopharmaceutical service provider and full service CRO for pharmaceutical, biotechnology and medical devices manufacturing companies with a vision of being an effective CRO that is economically compatible with the Indian pharma space. With innovative technologies and therapeutic expertise, Croissance Clinical Research helps its clients to deliver safe and effective therapeutics and maximize the returns.
Comprehensive Range of Services
Croissance Clinical Research possesses the capacity to coordinate phase II to IV trials on both national and international scales. The company performs all stages of clinical trials from feasibility to final study report with wide therapeutic experience and in-depth knowledge of local requirements. Croissance Clinical Research team is exposed in handling both paper and e-CRF based studies. The team is flexible in adapting to the sponsor specific tools to manage their data and all its statistical services are based on ICHGCP guidelines. Croissance Clinical Research performs site management services to act as the liaison between the site, the sponsor, and the conduct of the study. Their medical writing services are based on their extensive experience in the pharmaceutical industry. From protocol writing to the final study report preparation, their medical writers collaborate with biostatisticians and project team members to produce comprehensive and well structured documents for all stages of clinical development.
Satish Marukurthi, CEO of Croissance Clinical Research adds, “We always reverse calculate our budget, efforts and scope. We always tailor make our proposals and our teams to suit the need of the Indian clients. Because in India, people wanted to do something but never had revenues to do it. So, they could not go to big CROs because they're charging millions. I wanted to fill that gap. And to some extent, we are successful in that area. Our aim was to be the supporting industry that empowers the Indian pharma segment with good team and quality data. Our philosophy has always been to be flexible and match the client's needs”.
b>Vision for the Future
Mr. Satish Marukurthi further adds, “We are currently conducting a COVID vaccine study from a large US multinational and we already have hired employers for it in India, Mozambique and Nepal. So, the greatest achievement for us is starting our operations in Africa, with our own office and own staff. And in addition, we have started full fledged operations in Nepal. So, these are the two new countries we are venturing into, and I am looking forward to expand into other Asia Pacific regions like Singapore, Sri Lanka and Malaysia.”
Croissance Clinical Research possesses the capacity to coordinate phase II to IV trials on both national and international scales. The company performs all stages of clinical trials from feasibility to final study report with wide therapeutic experience and in-depth knowledge of local requirements. Croissance Clinical Research team is exposed in handling both paper and e-CRF based studies. The team is flexible in adapting to the sponsor specific tools to manage their data and all its statistical services are based on ICHGCP guidelines. Croissance Clinical Research performs site management services to act as the liaison between the site, the sponsor, and the conduct of the study. Their medical writing services are based on their extensive experience in the pharmaceutical industry. From protocol writing to the final study report preparation, their medical writers collaborate with biostatisticians and project team members to produce comprehensive and well structured documents for all stages of clinical development.
We always reverse calculate our budget, efforts and scope. We always tailor make our proposals and our teams to suit the need of the Indian clients
Satish Marukurthi, CEO of Croissance Clinical Research adds, “We always reverse calculate our budget, efforts and scope. We always tailor make our proposals and our teams to suit the need of the Indian clients. Because in India, people wanted to do something but never had revenues to do it. So, they could not go to big CROs because they're charging millions. I wanted to fill that gap. And to some extent, we are successful in that area. Our aim was to be the supporting industry that empowers the Indian pharma segment with good team and quality data. Our philosophy has always been to be flexible and match the client's needs”.
b>Vision for the Future
Mr. Satish Marukurthi further adds, “We are currently conducting a COVID vaccine study from a large US multinational and we already have hired employers for it in India, Mozambique and Nepal. So, the greatest achievement for us is starting our operations in Africa, with our own office and own staff. And in addition, we have started full fledged operations in Nepal. So, these are the two new countries we are venturing into, and I am looking forward to expand into other Asia Pacific regions like Singapore, Sri Lanka and Malaysia.”
